Afatinib, Erlotinib and Gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: A review

Onkologie(Czech Republic)

Volumn 36, Issue 9, 2013, Pages 510-518

  Köhler, Jens ^a   Schuler, Martin ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adenocarcinoma; Afatinib; EGFR mutation; EGFR TKI; Erlotinib; First line therapy; Gefitinib

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LOPERAMIDE; NAVELBINE; PACLITAXEL; SUNSCREEN;

ACNE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; FATIGUE; FLUID INTAKE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; LIVER; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULAR PATHOLOGY; MUTATION RATE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PARONYCHIA; PRESCRIPTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SIDE EFFECT; SMOKING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LUNG NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84884775038     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000354627     Document Type: Review

References (111)

1. Thun MJ, Hannan LM, Adams-Campbell LL, et al.: Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 2008;5:e185.
2. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Spiro SG, Silvestri GA: One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-529.
4. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
5. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
6. Croce CM: Oncogenes and cancer. N Engl J Med 2008;358:502-511.
7. Weinstein IB: Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-64.
8. Cohen S: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 1962; 237:1555-1562.
9. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174.
10. Ang KK, Berkey BA, Tu X, et al.: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62: 7350-7356.
11. Milas L, Fan Z, Andratschke NH, Ang KK: Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004;58:966-971.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
13. Thatcher N, Chang A, Parikh P, et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
14. Yang JC, Shih JY, Su WC, et al.: Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012;13:539-548.
15. Govindan R, Ding L, Griffith M, et al.: Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-1134.
16. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al.: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
17. Paez JG, Janne PA, Lee JC, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
18. Tang X, Shigematsu H, Bekele BN, et al.: EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005;65:7568-7572.
19. Yatabe Y: EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010;29:23-36.
20. Centeno I, Blay P, Santamaria I, et al.: Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer 2011;11:172.
21. Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
22. Tanaka T, Matsuoka M, Sutani A, et al.: Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer 2010;126:651-655.
23. Shigematsu H, Lin L, Takahashi T, et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
24. Shim HS, Lee da H, Park EJ, Kim SH: Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 2011;135:1329-1334.
25. Thu KL, Vucic EA, Chari R, et al.: Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. PLoS One 2012;7:e33003.
26. Wu M, Zhao J, Song SW, et al.: EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010;67:343-347.
27. Tsao MS, Sakurada A, Ding K, et al.: Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol 2011; 6:139-147.
28. Eberhard DA, Johnson BE, Amler LC, et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
29. Sakurada A, Shepherd FA, Tsao MS: Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. Clin Lung Cancer 2006;7(suppl 4):S138-S144.
30. Carey KD, Garton AJ, Romero MS, et al.: Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66: 8163-8171.
31. Massarelli E, Varella-Garcia M, Tang X, et al.: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-smallcell lung cancer. Clin Cancer Res 2007;13:2890-2896.
32. Burns DM, Anderson CM, Gray N: Do changes in cigarette design influence the rise in adenocarcinoma of the lung? Cancer Causes Control 2011; 22:13-22.
33. Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al.: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006;12:6049-6055.
34. Reck M, Buchholz E, Romer KS, et al.: Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. Clin Lung Cancer 2006;7:406-411.
35. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T: A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV nonsmall cell lung cancer. J Thorac Oncol 2009;4:214-219.
36. Jackman DM, Yeap BY, Lindeman NI, et al.: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007;25:760-766.
37. Hesketh PJ, Chansky K, Wozniak AJ, et al.: Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced nonsmall cell lung cancer and a performance status of 2. J Thorac Oncol 2008;3:1026-1031.
38. Crino L, Cappuzzo F, Zatloukal P, et al.: Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26:4253-4260.
39. Lilenbaum R, Axelrod R, Thomas S, et al.: Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced nonsmall-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-869.
40. Lee SM, Khan I, Upadhyay S, et al.: First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2012;13:1161-1170.
41. Morere JF, Brechot JM, Westeel V, et al.: Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 2010;70:301-307.
42. Goss G, Ferry D, Wierzbicki R, et al.: Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-2260.
43. Yang CH, Yu CJ, Shih JY, et al.: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive nonsmall-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753.
44. Niho S, Kubota K, Goto K, et al.: First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006;24:64-69.
45. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
46. Ebi N, Semba H, Tokunaga SJ, et al.: A phase II trial of gefitinib monotherapy in chemotherapynaive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:1166-1171.
47. Zhou C, Wu YL, Chen G, et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
48. Maemondo M, Inoue A, Kobayashi K, et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388.
49. Rosell R, Carcereny E, Gervais R, et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer ( EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
50. Mitsudomi T, Morita S, Yatabe Y, et al.: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
51. Dahabreh IJ, Linardou H, Siannis F, et al.: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010;16:291-303.
52. Petrelli F, Borgonovo K, Cabiddu M, Barni S: Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012;13:107-114.
53. Jackman DM, Miller VA, Cioffredi LA, et al.: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in prezviously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-5273.
54. Fukuoka M, Wu YL, Thongprasert S, et al.: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmall-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874.
55. Sequist LV, Yang JC, Yamamoto N, et al.: Phase III study of afatinib or cisplatin plus pemetrexed in patiens with metastatic lung adenocarinoma with EGFR mutations. J Clin Oncol 2013 DOI: 10,1200/JCO.2012.44,2806.
56. Yang JC, Hirsh V, Schuler M, et al.: Symptom control and quality of life in LUX-Lung 3: a phase III strudy of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013 DOI: 10,1200/JCO.2012.46,1764.
57. Wu JY, Yu CJ, Yang CH, et al.: First-or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008;178:847-853.
58. Zhang L, Ma S, Song X, et al.: Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012;13:466-475.
59. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
60. Oizumi S, Kobayashi K, Inoue A, et al.: Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012;17:863-870.
61. Asami K, Koizumi T, Hirai K, et al.: Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer 2011;12:387-392.
62. Gridelli C, Butts C, Ciardiello F, et al.: An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 2008;9:235-238.
63. Thomas M, Reuss A, Fischer JR, et al.: Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(suppl);abstr 7504.
64. Giaccone G, Herbst RS, Manegold C, et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-784.
65. Herbst RS, Giaccone G, Schiller JH, et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
66. Janne PA, Wang X, Socinski MA, et al.: Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012;30:2063-2069.
67. Oxnard GR, Arcila ME, Chmielecki J, et al.: New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17:5530-5537.
68. Yun CH, Mengwasser KE, Toms AV, et al.: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-2075.
69. Su KY, Chen HY, Li KC, et al.: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with nonsmall-cell lung cancer. J Clin Oncol 2012;30:433-440.
70. Yu HA, Arcila ME, Rekhtman N, et al.: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers. Clin Cancer Res 2013;19: 2240-2247.
71. Mink SR, Vashistha S, Zhang W, et al.: Cancer-associated fibroblasts derived from EGFR-TKIresistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res 2010;8:809-820.
72. Takezawa K, Pirazzoli V, Arcila ME, et al.: HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012;2:922-933.
73. Shigematsu H, Takahashi T, Nomura M, et al.: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-1646.
74. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K: Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 2005;103:1865-1873.
75. Sergina NV, Rausch M, Wang D, et al.: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007; 445:437-441.
76. Bean J, Riely GJ, Balak M, et al.: Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008;14:7519-7525.
77. Li D, Ambrogio L, Shimamura T, et al.: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-4711.
78. Miller VA, Hirsh V, Cadranel J, et al.: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-538.
79. Murakami H, Tamura T, Takahashi T, et al.: Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUXLung 4). Cancer Chemother Pharmacol 2012;69: 891-899.
80. Scagliotti GV, Parikh P, von Pawel J, et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
81. Einhorn LH: First-line chemotherapy for nonsmall-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 2008;26:3485-3486.
82. O'Brien ME, Borthwick A, Rigg A, et al.: Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. Br J Cancer 2006;95:1632-1636.
83. Ren S, Li Y, Li W, et al.: Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration 2012;84:431-435.
84. Schacher-Kaufmann S, Pless M: Acute fatal liver toxicity under erlotinib. Case Rep Oncol 2010;3: 182-188.
85. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S: Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012;78:8-15.
86. Perez-Soler R, Delord JP, Halpern A, et al.: HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345-356.
87. Hirsh V: Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011;18:126-138.
88. Saltz LB: Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 2003;1: 35-46; discussion 38-41, 45-36.
89. Maroun JA, Anthony LB, Blais N, et al.: Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 2007;14:13-20.
90. Nakagawa M, Nishimura T, Teramukai S, et al.: Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer-a retrospective analysis: JMTO LC03-02. BMC Res Notes 2009;2:157.
91. Yoneda KY, Hardin KA, Gandara DR, Shelton DK: Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer 2006;8(suppl 1):S31-S35.
92. Boyer MJ, Blackhall FH, Park K, et al.: Efficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). J Clin Oncol 2010;28(suppl 18s):abstr LBA7523.
93. Zhou C, Wu Y, Liu X, et al.: Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(suppl):abstr 7520.
94. Yang JC, Reguart N, Barinoff J, et al.: Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013;13:729-736.
95. Lacouture ME, Schadendorf D, Chu CY, et al.: Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013;13:721-728.
96. Kantarjian H, Shah NP, Hochhaus A, et al.: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-2270.
97. Zhou W, Ercan D, Chen L, et al.: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-1074.
98. Spigel DR, Ervin TJ, Ramlau R, et al.: Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29(suppl):abstr 7505.
99. Janjigian YY, Groen HJM, Horn L, et al.: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011;29(suppl):abstr 7525.
100. Nguyen KS, Kobayashi S, Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10: 281-289.
101. Cortot AB, Repellin CE, Shimamura T, et al.: Resistance to irreversible EGFR tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013;73:834-843.
102. West HL, Franklin WA, McCoy J, et al.: Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006;24:1807-1813.
103. Cadranel J, Quoix E, Baudrin L, et al.: IFCT-0401 trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol 2009;4:1126-1135.
104. Lee DH, Han JY, Lee HG, et al.: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005;11:3032-3037.
105. Jackman DM, Cioffredi L, Lindeman NI: Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol 2009;27(suppl 15S):abstr 8065.
106. Han JY, Park K, Kim SW, et al.: First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-1128.
107. Asahina H, Yamazaki K, Kinoshita I, et al.: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004.
108. Inoue A, Suzuki T, Fukuhara T, et al.: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-3346.
109. Sequist LV, Martins RG, Spigel D, et al.: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
110. Rosell R, Moran T, Queralt C, et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
111. Inoue A, Kobayashi K, Usui K, et al.: First-line gefitinib for patients with advanced non-smallcell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-1400.